In today’s world, the health sector is among the few areas experiencing an incredible but crucial growth. Owing to the rise in cases of ailments triggered by the lifestyle changes, various institutions have made it their daily mandate to implement new treatment means. Amicus Therapeutics, Inc. is among the few but notable companies setting their foot forward in the biotechnology sector precisely.
Globally, the company is known for the uncovering, developing and marketing of acute treatments for devastating genetic diseases. Amicus was founded back in 2002 and has its headquarters in Cranbury, New Jersey. Today, the company stands as a public entity under FOLD, NASDAQ’s trading symbol. Before, the successful business was funded by distinguished firms such as Radius Ventures, Canaan Partners, and New Enterprise Associates among others.
Amicus Therapeutics specializes in products broadly based on the Chaperone-Advanced Replacement Therapy platform. With time, the company has been keen on the development of enzyme replacement therapies. One of its important products includes migalastat HCl, a product that can be used for the treatment of fabry diseases when mixed with enzyme replacements. Also, migalastat can be used as a monotherapy.
Back in 2014, Amicus Therapeutics was named as the best developer of small molecule pharmacological chaperones. However, earlier the same year, the company had no marketed products even with migalastat (Galafold) in place. Practically, Amicus has no manufacturing abilities hence rely on contract manufacturing solo. However, the company own a research site based in San Diego that was established in 2008.
Every successful business’s story is characterized by ups and downs, and Amicus is no ordinary. For example, in 2009, the company was hit by a major financial setback due to the termination of a multi-year partnership agreement with Shire (YahooFinance). Later, the company received funding from various foundations to support its researchers.
Within time, Amicus Therapeutics has acquired various competitive companies such as Callidus Biopharma and Scioderm. Today, John Crowley serves as the company’s CEO, a position that he has held since 2005. Bradley Campbell serves as the company’s COO while William D. Baird III assists as the chief financial officer. Last but not least on the company’s executive team is David Lockhart who serves as the chief scientific officer, the heart of the business.
More of Amicus Therapeutics on